预约演示
更新于：2026-01-29
Risperidone
利培酮
更新于：2026-01-29
概要
基本信息
简介利培酮（商品名为：RISPERDAL®）是一种非典型抗精神病药物。该药品由强生公司开发，于1993年12月29日获得美国食品药品监督管理局（FDA）批准。利培酮用于治疗精神分裂症，以及与双相I型障碍相关的急性躁狂或混合发作，可作为单药治疗或与锂或丙戊酸辅助治疗。此外，该药品还被批准用于治疗与自闭症谱系障碍相关的烦躁情绪。该药品通过抑制多巴胺2型（D2）和5-羟色胺2型（5HT2）受体结合起作用，这被认为是其治疗精神分裂症的疗效贡献之一。利培酮一般耐受性较好，但可能会引起体重增加、嗜睡和锥体外系症状等副作用。 |
药物类型 小分子化药 |
别名 Risperdal OD、Risperidone (JP17/USP/INN)、Risperidone for Depot Suspension + [46] |
作用方式 拮抗剂 |
作用机制 5-HT2A receptor拮抗剂(5-羟色胺2A受体拮抗剂)、D2 receptor拮抗剂(多巴胺D2受体拮抗剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (1993-12-29), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H27FN4O2 |
InChIKeyRAPZEAPATHNIPO-UHFFFAOYSA-N |
CAS号106266-06-2 |
关联
560
项与 利培酮 相关的临床试验NCT06768944
The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults
IRCT20250611066179N1
Investigating the effect of risperidone on delirium indices in patients admitted to the PICU
CTRI/2025/09/095098
An Open-Label, Balanced, Multicentric, Randomized, Two Treatment, Two-Period with Two Consecutive Profile in Single Period, Two Sequence, Crossover, Multiple Dose, Steady State Bioequivalence Study of Risperidone Long-Acting Injection 25 Mg/ Vial (Test Drug From Intas Pharmaceuticals Ltd., India,) against Risperdal CONSTA® (Risperidone) Long-Acting Injection 25 Mg/Vial (Janssen-Cilag GmbH, Germany) In Patients Needing Maintenance Treatment For Schizophrenia - NIL
100 项与 利培酮 相关的临床结果
登录后查看更多信息
100 项与 利培酮 相关的转化医学
登录后查看更多信息
100 项与 利培酮 相关的专利（医药）
登录后查看更多信息
11,246
项与 利培酮 相关的文献（医药）2026-04-01JOURNAL OF AFFECTIVE DISORDERS
The Ottawa sunglasses at night study: A randomized controlled trial of blue-blocking glasses for mania
Article
作者: Fiedorowicz, Jess G ; Mikhail, Eric ; Nguyen, Thanh ; Siddiqi, Sara ; Solmi, Marco ; Burns, Joseph K ; Smith, Andrew L ; Yu, Jessica ; Robillard, Rébecca
BACKGROUND:
Dysregulation of the endogenous biological clock is central to the pathophysiology of mania. The strongest time-giving signal is short wavelength (blue) light to which intrinsically photosensitive retinal ganglion cells containing the pigment melanopsin are primarily sensitive. Blocking blue light in the evening produces a physiological darkness condition.
METHODS:
In a randomized controlled trial with blinded raters conducted in a large academic hospital (Ontario, Canada), inpatients with mania were randomized to adjunctive blue-blocking glasses or lightly tinted glasses until discharge or up to two weeks. The primary outcome, improvement in manic symptoms on the Young Mania Rating Scale (YMRS), was assessed as a group by time interaction using linear mixed models. Secondary outcomes included differences in medication use. Registered on clinicaltrials.gov: NCT05206747.
RESULTS:
A total of 42 participants were randomized to blue-blocking glasses (n = 20) or lightly tinted glasses (n = 22). Those prescribed blue-blocking glasses did not show significant improvements in the YMRS relative to those with control lenses (difference of change in estimated marginal means at week 2 favoring control group by 2.1 points on YMRS, group ∗ time interaction p = 0.93). Average antipsychotic dose (7.2 vs. 7.1 mg/day risperidone equivalents, p = 0.29) and benzodiazepine dose (0.7 mg/day lorazepam equivalents for both groups, p = 0.67) did not differ significantly between groups. There were no differences in other secondary outcomes.
CONCLUSIONS:
Despite the biological plausibility of the intervention and promising prior studies, blue-blocking glasses were not superior to lightly tinted lenses in their effects of manic symptoms in this randomized controlled trial in an inpatient setting.
2026-03-01NEUROPHARMACOLOGY
Cell models to probe the biological bases of antipsychotic-induced metabolic Syndrome: towards an individual specific approach
Review
作者: Pergola, Giulio ; De Mastro, Laura ; Saltarelli, Silvia ; Fiore, Maria ; Bertolino, Alessandro ; Ianniello, Antonia ; D'Ambrosio, Enrico ; Rampino, Antonio ; Favia, Maria
BACKGROUND:
Individuals with major psychiatric disorders are at an increased risk of developing Metabolic Syndrome (MetS), partly attributed to the dysmetabolic side effects of Second-Generation Antipsychotics (SGAs). In vitro cell models of peripheral tissues provide a valid platform to investigate the biochemical and molecular alterations induced by SGAs at the peripheral level in conjunction with their effects on the central nervous system. This scoping review summarizes two decades of studies utilizing established cell lines and primary rodent cells to examine the direct dysmetabolic effects of antipsychotics (APs) on lipid and glucose metabolism, inflammatory pathways, and mitochondrial function.
METHODS:
We identified published scientific literature in the PubMed database using the following search strategy: ("antipsychotic" OR "olanzapine" OR "clozapine" OR "risperidone" OR "quetiapine" OR "haloperidol") AND ("metabolic syndrome" OR "insulin action" OR "insulin resistance" OR "up-regulation" OR "down-regulation" OR "dyslipidemia") AND (cell models).
RESULTS:
Out of 121 articles identified, 21 met the eligibility criteria and were included in the review, with their methods and findings organized according to the AP-affected biological processes implicated in MetS.
CONCLUSIONS:
Independent studies on cell models confirm the AP-pathogenic role on gene and protein expression regulation involved in lipid and glucose metabolism, inflammatory processes, and impairments at the mitochondrial level. In the final section of the manuscript, we highlight the potential of individual-specific stem-cell-based models, like induced pluripotent stem cells, to investigate gene-by-medication interactions relevant to AP-induced MetS. However, these stem-cell approaches fall outside the scope of the present review and were not included in our literature search.
2026-03-01GERIATRIC NURSING
Examining pharmacological and demographic factors among male and female alzheimer’s disease patients diagnosed with attention concentration disorder and cognitive communication disorder
Article
作者: Nathaniel, Adebobola I ; Agbomi, Lidadi L ; Roley, Laurie Theriot ; Nathaniel, Thomas I ; Desai, Ashna ; Nathaniel, Emmanuel I ; Goodwin, Richard
OBJECTIVE:
This study examines the differences between male and female Alzheimer's Disease patients diagnosed with Attention Concentration Deficit (ADACD) and Cognitive Communicative Disorder (ADCCD), focusing on pharmacological and demographic factors.
METHOD:
A multivariate analysis was conducted to identify pharmacological and demographic factors associated with ADACD and ADCCD in male and female patients.
RESULTS:
In the adjusted analysis for male patients, use of donepezil (OR = 1.683, 95 % CI: 1.172-2.417, p = 0.005), and risperidone (Risperdal) use (OR = 3.177, 95 % CI: 1.841-5.484, p < 0.001) were significantly associated with ADCCD. The use of memantine (OR = 0.189, 95 % CI: 0.091-0.393, p < 0.001), aripiprazole (OR = 0.065, 95 % CI: 0.015-0.278, p < 0.001), were associated with ADACD. For female patients, citalopram use (OR = 2.470, 95 % CI: 1.751-3.484, p < 0.001) was associated with ADCCD.
CONCLUSION:
These results underscore the urgent need to establish strategies aimed at addressing sex disparities in the care of ADACD and ADCCD patients.
100 项与 利培酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 自闭症 | 美国 | 2006-10-06 | |
| 情绪易怒 | 美国 | 2006-10-06 | |
| 躁郁症1型 | 美国 | 2003-12-04 | |
| 攻击 | 韩国 | 2003-08-02 | |
| 阿尔茨海默症 | 韩国 | 2003-08-02 | |
| 躁狂 | 韩国 | 2003-08-02 | |
| 自残行为 | 韩国 | 2003-08-02 | |
| 躁郁症 | 美国 | 2002-03-03 | |
| 精神分裂症 | 美国 | 1993-12-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性精神分裂症 | 临床3期 | 美国 | 2014-04-01 | |
| 自杀意念 | 临床3期 | 美国 | 2004-06-01 | |
| 创伤后应激障碍 | 临床3期 | 美国 | 2004-04-01 | |
| 广泛性焦虑障碍 | 临床3期 | 美国 | 2004-02-01 | |
| 恐慌 | 临床3期 | 美国 | 2004-02-01 | |
| 躁郁症2型 | 临床3期 | - | 2004-01-01 | |
| 儿童行为障碍 | 临床3期 | - | 2003-09-01 | |
| 学习障碍 | 临床3期 | - | 2003-09-01 | |
| 难治性抑郁症 | 临床3期 | - | 2002-10-01 | |
| 难治性抑郁症 | 临床3期 | - | 2002-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 160 | (Conventional Dose) | 簾構壓觸遞製繭積遞衊(夢築積衊鏇糧願遞築積) = 憲顧鏇艱廠繭積艱襯糧 獵範願顧範遞鑰艱網襯 (廠鬱襯壓築鏇遞築廠構, 1.2) 更多 | - | 2025-08-06 | ||
(High Dose Group) | 簾構壓觸遞製繭積遞衊(夢築積衊鏇糧願遞築積) = 艱鹽顧積觸網憲衊窪願 獵範願顧範遞鑰艱網襯 (廠鬱襯壓築鏇遞築廠構, 1.3) 更多 | ||||||
NEWS 人工标引  | N/A | - | 鹽選觸壓築遞蓋齋鑰衊(艱齋網遞鬱廠餘襯糧鏇) = 網窪窪蓋鹹鏇積窪艱廠 遞鏇壓構鏇壓廠膚窪鬱 (夢鬱襯膚餘鏇蓋淵鬱簾 ) 更多 | 积极 | 2025-05-31 | ||
Second Generation Oral Antipsychotics (SGOAs) | 鹽選觸壓築遞蓋齋鑰衊(艱齋網遞鬱廠餘襯糧鏇) = 鑰獵積鑰艱網醖積鹹遞 遞鏇壓構鏇壓廠膚窪鬱 (夢鬱襯膚餘鏇蓋淵鬱簾 ) 更多 | ||||||
N/A | 1,684 | D2 receptor antagonists (D2RAs) | 觸廠獵襯積獵壓範構獵(憲顧鑰網醖廠構夢構窪) = 簾製齋願選鑰構齋顧構 製艱鑰繭糧夢製憲餘淵 (憲夢獵觸顧鏇夢繭鬱糧 ) | 不佳 | 2025-04-07 | ||
临床2期 | 6 | risperidone+BioStamp nPoint device | 簾製憲艱網壓獵醖築簾(餘壓蓋襯製衊糧顧積遞) = 齋壓糧築憲範顧蓋築鬱 齋積衊憲築範廠願製蓋 (膚鹽願醖艱繭製獵艱齋, 齋遞壓鏇夢鏇製顧獵鹹 ~ 積鑰夢遞鏇鏇夢範衊積) 更多 | - | 2025-03-21 | ||
临床1/2期 | 34 | (DLP-114 Alpha-4 (6-months)) | 齋積壓顧醖積窪淵鬱願 = 蓋鬱鹹壓繭遞獵壓淵襯 廠鹽餘鹹鏇糧鑰選觸糧 (網簾鏇構餘觸鬱淵願醖, 簾鏇膚餘繭範糧鑰蓋艱 ~ 鹹餘選製積膚遞觸膚鹽) 更多 | - | 2024-12-27 | ||
(DLP-114 Alpha-7 (12-months)) | 齋積壓顧醖積窪淵鬱願 = 憲襯遞憲憲遞遞顧壓壓 廠鹽餘鹹鏇糧鑰選觸糧 (網簾鏇構餘觸鬱淵願醖, 夢衊膚願繭醖鏇築窪膚 ~ 蓋築觸遞簾鏇蓋壓顧艱) 更多 | ||||||
N/A | 36 | 襯窪襯壓餘製網鏇蓋鏇(鑰製艱窪顧鏇網鑰構獵) = 繭憲積餘鬱淵衊積顧顧 鏇糧鹽構鑰鏇衊簾簾構 (醖範艱鹽鬱鑰顧艱構蓋, 6.45 ~ 15.8) 更多 | 积极 | 2024-09-27 | |||
临床4期 | 26 | (Patient) | 膚糧鏇衊網積鏇獵構鬱(糧築窪積蓋網夢齋憲廠) = 壓構構構網餘積觸鹽獵 糧網齋蓋襯鑰蓋簾壓觸 (築選蓋構蓋簾衊選獵鏇, 製範窪鹹製蓋壓憲範鬱 ~ 選構鹽糧獵積網餘鹽願) 更多 | - | 2024-05-06 | ||
(Control) | 膚糧鏇衊網積鏇獵構鬱(糧築窪積蓋網夢齋憲廠) = 壓夢鏇鏇壓衊顧繭範憲 糧網齋蓋襯鑰蓋簾壓觸 (築選蓋構蓋簾衊選獵鏇, 選艱糧壓簾積艱築製鏇 ~ 衊遞襯選餘積夢鹽簾憲) 更多 | ||||||
临床3期 | 390 | RISVAN 75 mg | 餘製鹽鏇蓋糧艱齋襯鬱(獵淵夢繭積築築壓築壓) = 衊齋蓋襯糧夢夢憲觸遞 鹹鹽鬱窪壓繭衊膚醖鏇 (蓋鑰鑰鬱簾壓願製顧鹽, 1.51) | 积极 | 2024-03-29 | ||
RISVAN 100 mg | 餘製鹽鏇蓋糧艱齋襯鬱(獵淵夢繭積築築壓築壓) = 窪窪選築廠顧餘齋鬱願 鹹鹽鬱窪壓繭衊膚醖鏇 (蓋鑰鑰鬱簾壓願製顧鹽, 1.54) | ||||||
临床1/2期 | 28 | 艱壓顧齋餘醖鏇獵襯壓(選醖膚壓襯襯築憲遞製) = No serious adverse events (AEs) attributed to DLP-114 were reported, and DLP-114 was well tolerated for up to 12 months, including the initial placement and follow-up removal procedures 衊築衊窪醖築淵餘繭獵 (餘築憲範壓構積築衊鹽 ) 更多 | 积极 | 2023-11-16 | |||
临床3期 | 544 | 獵願衊鏇遞鹹壓積夢膚(齋齋鏇顧憲積餘齋壓繭) = significantly prolonged by 5·0 times with TV-46000 once monthly (hazard ratio, 0·200 [95% CI 0·109–0·367]; p<0·0001) and by 2·7 times with TV-46000 once every 2 months (0·375 [0·227–0·618]; p<0·0001) versus placebo. 網積餘壓窪製齋齋艱範 (遞膚鑰夢構範醖選鏇構 ) 更多 | 积极 | 2023-11-01 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用